BioSpace News Archive

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), today announced that the first patient has been dosed in the Company’s Phase 1 clinical trial of IO-202, a first-in-class myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B4 (LILRB4, also known as ILT3) for the treatment of patients with advanced solid tumors (NCT05309187).

This settlement resolves these business disputes, and upon closing of the Settlement Agreement, all three lawsuits will be dismissed with prejudice.

Surf Bio, Inc., a biopharmaceutical company commercializing a novel drug stabilization platform, announced a $16 million Series Seed round of funding.

CytoRecovery, Inc., a leader in the marker free enrichment, sorting, and recovery of live cells, presented recent study results at the American Association for Cancer Research (AACR) Annual Meeting 2022 currently being held in New Orleans.

Increasing prevalence of infectious diseases and genetic disorders across the globe, rapid advancements in genomic sequencing techniques, and rising number of genomic research based activities are some key factors expected to drive global market growth.

Apotex Corp. announced today its release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane® in the United States.

Increasing research in biotechnology and pharmaceutical sector, rising global prevalence of infectious and chronic diseases, and rapid advancements in protein therapeutics are some key factors expected to drive market revenue growth.

Immunicom, Inc., a clinical-stage biotechnology company pioneering a first-of-its-kind technology platform for immuno-oncology, announced that Dr. Peter Farrell and Michael E. Lehman have joined the Company’s Board of Directors.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented three preclinical poster presentations and one preclinical oral presentation at the 2022 American Cancer Research Association (AACR) Annual Meeting.

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced it proposes to elect Maria Fardis, Ph.D., MBA, to its Board of Directors at the Company’s upcoming annual general of shareholders meeting to be held later this year.